Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | CD19 t-haNK cells |
Trade Name | |
Synonyms | |
Drug Descriptions |
CD19 t-haNK cells are activated natural killer (NK) cells engineered to express a high affinity Fc receptor and a chimeric antigen receptor (CAR) targeting CD19, which potentially induce tumor cell killing (PMID: 35400595). |
DrugClasses | CD19 Immune Cell Therapy 62 |
CAS Registry Number | NA |
NCIT ID | NA |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
CD19 t-haNK cells | CD19 t-haNK cells | 0 | 0 |
CD19 t-haNK cells + Nogapendekin alfa inbakicept + Rituximab | CD19 t-haNK cells Nogapendekin alfa inbakicept Rituximab | 0 | 1 |
CD19 t-haNK cells + Rituximab | CD19 t-haNK cells Rituximab | 0 | 1 |